background image
Inquisit Logo

Powered by Windows Media Services. Get Windows Media Player
Share      Print this page
Price:  Free
  On Demand  CE  Differentiating GLP-1 Agonists from other Incretin-Based Therapies for Diabetes

Educational Grant From Novo Nordisk
Diabetes is a serious and chronic disease affecting some 18 million Americans. Each year, approximately 800,000 people are diagnosed with diabetes, with Type 2 diabetes accounting for 90-95% of all cases. The prevalence of diabetes has increased steadily over the last 2 decades and with an aging US population and the increased prevalence of obesity among Americans, the incidence is expected to continue to rise. Diabetes carries with it a high rate of morbidity and mortality – primarily from microvascular complications and cardiovascular disease. Studies such as the UKPDS and DCCT have shown that maintaining glycemic control is critical in preventing and delaying the complications of diabetes. This program reviews the pathophysiology of type 2 diabetes and differentiates the effects of GLP-1 agonists versus other incretin-based therapies.
Program Objectives:
  • Describe the multiple pathophysiologic defects that occur in type 2 diabetes.
  • Describe the incretin effect and the physiologic role of GLP-1 in the body.
  • Identify strategies to address incretin deficiency.
  • Differentiate between the physiologic effects of DPP-IV inhibitors and the pharmacologic effects of GLP-1 agonists.
  • Discuss why GLP-1 agonists have utility in managing type 2 diabetes.
  • Differentiate between the 2 FDA approved GLP-1 agonists on the market.
  • Identify patients who are likely to benefit from therapy with a GLP-1 agonist.
  • Describe the most common side effects patients experience when using GLP-1 agonists.
Learning Objectives for Pharmacy Technicians:
  • Describe 2 key defects occurring in type 2 diabetes.
  • Describe the incretin effect.
  • Identify 2 approaches to addressing incretin deficiency
  • Identify commonly prescribed medications that involve the incretin system
  • Describe the most common side effects patients experience when using GLP-1 agonists.
Scott R. Drab, PharmD, CDE, BC-ADM, Assistant Professor, Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy
   Director, University Diabetes Care Associates

  Dr. Drab is an assistant professor of Pharmacy & Therapeutics and Director of University Diabetes Care Associates at the University of Pittsburgh School of Pharmacy.

Dr. Drab's efforts in contributing to pharmaceutical care led to the creation of one of the first pharmacist-run diabetes care centers located in a community independent pharmacy. As a Certified Diabetes Educator and director of the clinic, he is responsible for care plan development, education, and patient follow up. He has managed the care of hundreds of diabetic patients over the years, improving clinical health outcomes. In addition to the direct patient care responsibilities, Dr. Drab is responsible for providing drug information to the surrounding medical community and provides outreach education to benefit the greater good of the community. Today the University Diabetes Care Associates serves as a model and prototype for future care centers.

Dr. Drab wishes to disclose that he is a consultant for Novo Nordisk.
Requirements for Completion | Statement of Completion | CE Contact Hours | Disclosures
© Copyright 2014. All rights reserved. | Privacy Policy | Terms Of Use | Help